Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.46 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10010145 | 1.00 | ALDH1A1 (0.54) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL26305201 | 0.96 | LPAR1 (0.49) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL19019736 | 0.89 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL8636549 | 0.87 | USP2 (0.53) | LPAR1LPAR3 | |
| SCHEMBL7714993 | 0.84 | LPAR1 (0.51) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL898772 | 0.84 | TRPV1 (0.49) | ALDH1A1CNR1CNR2 | |
| SCHEMBL24710793 | 0.83 | ALDH1A1 (0.59) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL903074 | 0.83 | USP2 (0.54) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL17744012 | 0.83 | USP2 (0.54) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL17744011 | 0.83 | USP2 (0.54) | ALDH1A1CNR1CNR2LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288146-A1 | NOVEL TRIALKYL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2014-09-25 | — | — | US | disclosed |
| US-20140288146-A1 | NOVEL TRIALKYL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2014-09-25 | — | — | US | disclosed |
| US-20140288146-A1 | NOVEL TRIALKYL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2014-09-25 | — | — | US | disclosed |
| US-8466122-B2 | Trialkyl cationic lipids and methods of use thereof | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2013-06-18 | — | — | US | disclosed |
| US-8466122-B2 | Trialkyl cationic lipids and methods of use thereof | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2013-06-18 | — | — | US | disclosed |
| US-8466122-B2 | Trialkyl cationic lipids and methods of use thereof | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2013-06-18 | — | — | US | disclosed |
| US-20120172411-A1 | NOVEL TRIALKYL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2012-07-05 | — | — | US | disclosed |
| US-20120172411-A1 | NOVEL TRIALKYL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2012-07-05 | — | — | US | disclosed |
| US-20120172411-A1 | NOVEL TRIALKYL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288146-A1 | NOVEL TRIALKYL CATIONIC LIPIDS AND METHODS OF USE THEREOF | NPC1L1, LDLR, CETP | ALDH1A1 4746/4885CNR1 4580/4885CNR2 4625/4885 |
| US-20120172411-A1 | NOVEL TRIALKYL CATIONIC LIPIDS AND METHODS OF USE THEREOF | NPC1L1, LDLR, CETP | ALDH1A1 4746/4885CNR1 4580/4885CNR2 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.